Basic Information
Neuronascent discovers and develops first-in-class small molecule therapies based on the science of neurogenesis, targeting depression, neurodegenerative diseases (including Alzheimer's and Parkinson's), and Down syndrome.
NeuroNascent, Inc.
--
less than 15 people
January 01, 2004
info@neuronascent.com
Enterprise Profile
Industrial Sector
Concept
Application Scenarios